Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics

Core Insights - OPKO Health reported $156.8 million in revenue for the quarter ended June 2025, reflecting a year-over-year decline of 13.9% and an EPS of -$0.19 compared to -$0.01 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $165.22 million by 5.09%, and the EPS was also below the consensus estimate of -$0.12, resulting in a surprise of -58.33% [1] Revenue Breakdown - Revenue from the transfer of intellectual property and other was $15 million, below the five-analyst average estimate of $20.07 million, but showed a year-over-year increase of 22% [4] - Revenue from products was $40.7 million, slightly below the estimated $40.88 million, with a year-over-year change of 0.5% [4] - Revenue from services was $101.1 million, which was lower than the estimated $104.29 million, representing a significant year-over-year decline of 21.9% [4] Stock Performance - OPKO Health's shares have remained unchanged over the past month, while the Zacks S&P 500 composite increased by 2.7% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance compared to the broader market in the near term [3]